DRMA vs IMRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

DRMA

61.1
AI Score
VS
DRMA Wins

IMRX

59.5
AI Score

Investment Advisor Scores

DRMA

61score
Recommendation
BUY

IMRX

60score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DRMA IMRX Winner
Net Income -4.81M -53.47M DRMA
Operating Income -4.94M -58.41M DRMA
ROE -138.0% -59.0% IMRX
ROA -90.5% -52.1% IMRX
Total Assets 5.32M 102.58M IMRX
Cash 4.41M 59.41M IMRX
Current Ratio 3.40 11.35 IMRX
Free Cash Flow -5.01M -49.31M DRMA

Relative Price Performance (Last 90 Days)

DRMA 1M: -14.6% · 3M: -17.2% IMRX 1M: -16.9% · 3M: -22.4%

Current Technical Phase

DRMA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.5%), weak momentum, RSI 40

RSI (14): 40.0 · Price: $1.11

IMRX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.1%), weak momentum, RSI 31

RSI (14): 31.4 · Price: $4.03

Fundamentals Snapshot

Metric DRMA IMRX
Market Cap — —
Forward P/E -0.8 -3.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -1.0%
Gross Margin — 349.1%
Operating Margin 0.0% 0.0%
EPS -4.20 -0.93
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DRMA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.